Argenica Therapeutics (AGN) H1 2025 earnings summary

Executive summary

• Focused on research and development of a neuroprotective therapeutic drug, with ongoing Phase 2 clinical trials and non-clinical studies for additional indications.

• Loss for the half-year ended 31 December 2024 was $1,187,221, an improvement from $1,409,556 in the prior corresponding period.

• No significant changes in the state of affairs or subsequent events affecting future operations were reported.

Financial highlights

• Total income for the half-year was $3,107,366, up from $2,404,193 year-over-year, driven by a higher R&D tax incentive rebate and increased interest income.

• Research and development costs rose to $2,916,679 from $2,819,175 year-over-year, reflecting ongoing clinical and regulatory activities.

• Net operating cash outflows were $1,177,279, slightly higher than $1,137,200 in the prior period.

• Cash and cash equivalents at 31 December 2024 were $15,076,139, down from $15,912,660 at 30 June 2024.

• Net asset position at period end was $13,193,411, compared to $13,950,835 at 30 June 2024.

Outlook and guidance

• Business model remains highly dependent on successful clinical development, future funding, regulatory approvals, and broader economic factors.